FinancialContent

Articles published by Biogen Inc.

< Previous 1 2 3 4 Next >
News headline image
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
Biogen Completes Acquisition of RayThera Inc.
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Appoints Michael J. Parini as Chief Legal Officer
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
Biogen Announces Board Chair Transition
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
News headline image
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
News headline image
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB
News headline image
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB STOK
News headline image
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
News headline image
Biogen Completes Acquisition of Alcyone Therapeutics
From Biogen Inc.
Via GlobeNewswire
Tickers BIIB IONS
< Previous 1 2 3 4 Next >